Treatment and outcomes of post-transplant lymphoproliferative disease: A single institution study

Francis K. Buadi, Meyer R. Heyman, Christopher Gocke, Aaron P. Rapoport, Roger Hakimian, Stephen T. Bartlett, Clarence Sarkodee-Adoo

Research output: Contribution to journalArticle

Abstract

Post-transplant lymphoproliferative disorders (PTLD) complicate up to 10% of solid organ transplants. This retrospective study was conducted to review the PTLD experience among 2,300 recipients of solid organ or allogeneic bone marrow transplants from a single institution. Twenty-seven cases of PTLD were identified, leading to an overall incidence of 1.2%. Polymorphic B cell hyperplasia/lymphoma was the most common type. The median time to development of PTLD was 8.4 months. Ten patients had localized (stage I or II) disease, and 12 patients presented with B symptoms. Nine patients each were treated with systemic chemotherapy or surgical resection as part of the initial therapy. After a median follow-up duration of 2.6 years, the median survival has not been reached. There were no late relapses of PTLD, and 17 patients remain alive. Age, sex, organ source, LDH, stage, presence of extranodal disease, or presentation with B symptoms did not influence overall survival when examined by Cox proportional hazard model. Thirteen patients retained their graft function throughout PTLD treatment. This study confirms the ability to treat a significant proportion of PTLD patients with chemotherapy or surgical resection (depending on presentation), without sacrificing graft function in those receiving chemotherapy.

Original languageEnglish (US)
Pages (from-to)208-214
Number of pages7
JournalAmerican Journal of Hematology
Volume82
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Lymphoproliferative Disorders
Transplants
Drug Therapy
Survival
B-Cell Lymphoma
Proportional Hazards Models
Hyperplasia
Retrospective Studies
Bone Marrow
Recurrence
Incidence
Therapeutics

Keywords

  • Lymphoproliferative disorder
  • Post-transplant

ASJC Scopus subject areas

  • Hematology

Cite this

Buadi, F. K., Heyman, M. R., Gocke, C., Rapoport, A. P., Hakimian, R., Bartlett, S. T., & Sarkodee-Adoo, C. (2007). Treatment and outcomes of post-transplant lymphoproliferative disease: A single institution study. American Journal of Hematology, 82(3), 208-214. https://doi.org/10.1002/ajh.20795

Treatment and outcomes of post-transplant lymphoproliferative disease : A single institution study. / Buadi, Francis K.; Heyman, Meyer R.; Gocke, Christopher; Rapoport, Aaron P.; Hakimian, Roger; Bartlett, Stephen T.; Sarkodee-Adoo, Clarence.

In: American Journal of Hematology, Vol. 82, No. 3, 03.2007, p. 208-214.

Research output: Contribution to journalArticle

Buadi, FK, Heyman, MR, Gocke, C, Rapoport, AP, Hakimian, R, Bartlett, ST & Sarkodee-Adoo, C 2007, 'Treatment and outcomes of post-transplant lymphoproliferative disease: A single institution study', American Journal of Hematology, vol. 82, no. 3, pp. 208-214. https://doi.org/10.1002/ajh.20795
Buadi, Francis K. ; Heyman, Meyer R. ; Gocke, Christopher ; Rapoport, Aaron P. ; Hakimian, Roger ; Bartlett, Stephen T. ; Sarkodee-Adoo, Clarence. / Treatment and outcomes of post-transplant lymphoproliferative disease : A single institution study. In: American Journal of Hematology. 2007 ; Vol. 82, No. 3. pp. 208-214.
@article{ee6814b614f24b76bd85444ffbc81501,
title = "Treatment and outcomes of post-transplant lymphoproliferative disease: A single institution study",
abstract = "Post-transplant lymphoproliferative disorders (PTLD) complicate up to 10{\%} of solid organ transplants. This retrospective study was conducted to review the PTLD experience among 2,300 recipients of solid organ or allogeneic bone marrow transplants from a single institution. Twenty-seven cases of PTLD were identified, leading to an overall incidence of 1.2{\%}. Polymorphic B cell hyperplasia/lymphoma was the most common type. The median time to development of PTLD was 8.4 months. Ten patients had localized (stage I or II) disease, and 12 patients presented with B symptoms. Nine patients each were treated with systemic chemotherapy or surgical resection as part of the initial therapy. After a median follow-up duration of 2.6 years, the median survival has not been reached. There were no late relapses of PTLD, and 17 patients remain alive. Age, sex, organ source, LDH, stage, presence of extranodal disease, or presentation with B symptoms did not influence overall survival when examined by Cox proportional hazard model. Thirteen patients retained their graft function throughout PTLD treatment. This study confirms the ability to treat a significant proportion of PTLD patients with chemotherapy or surgical resection (depending on presentation), without sacrificing graft function in those receiving chemotherapy.",
keywords = "Lymphoproliferative disorder, Post-transplant",
author = "Buadi, {Francis K.} and Heyman, {Meyer R.} and Christopher Gocke and Rapoport, {Aaron P.} and Roger Hakimian and Bartlett, {Stephen T.} and Clarence Sarkodee-Adoo",
year = "2007",
month = "3",
doi = "10.1002/ajh.20795",
language = "English (US)",
volume = "82",
pages = "208--214",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment and outcomes of post-transplant lymphoproliferative disease

T2 - A single institution study

AU - Buadi, Francis K.

AU - Heyman, Meyer R.

AU - Gocke, Christopher

AU - Rapoport, Aaron P.

AU - Hakimian, Roger

AU - Bartlett, Stephen T.

AU - Sarkodee-Adoo, Clarence

PY - 2007/3

Y1 - 2007/3

N2 - Post-transplant lymphoproliferative disorders (PTLD) complicate up to 10% of solid organ transplants. This retrospective study was conducted to review the PTLD experience among 2,300 recipients of solid organ or allogeneic bone marrow transplants from a single institution. Twenty-seven cases of PTLD were identified, leading to an overall incidence of 1.2%. Polymorphic B cell hyperplasia/lymphoma was the most common type. The median time to development of PTLD was 8.4 months. Ten patients had localized (stage I or II) disease, and 12 patients presented with B symptoms. Nine patients each were treated with systemic chemotherapy or surgical resection as part of the initial therapy. After a median follow-up duration of 2.6 years, the median survival has not been reached. There were no late relapses of PTLD, and 17 patients remain alive. Age, sex, organ source, LDH, stage, presence of extranodal disease, or presentation with B symptoms did not influence overall survival when examined by Cox proportional hazard model. Thirteen patients retained their graft function throughout PTLD treatment. This study confirms the ability to treat a significant proportion of PTLD patients with chemotherapy or surgical resection (depending on presentation), without sacrificing graft function in those receiving chemotherapy.

AB - Post-transplant lymphoproliferative disorders (PTLD) complicate up to 10% of solid organ transplants. This retrospective study was conducted to review the PTLD experience among 2,300 recipients of solid organ or allogeneic bone marrow transplants from a single institution. Twenty-seven cases of PTLD were identified, leading to an overall incidence of 1.2%. Polymorphic B cell hyperplasia/lymphoma was the most common type. The median time to development of PTLD was 8.4 months. Ten patients had localized (stage I or II) disease, and 12 patients presented with B symptoms. Nine patients each were treated with systemic chemotherapy or surgical resection as part of the initial therapy. After a median follow-up duration of 2.6 years, the median survival has not been reached. There were no late relapses of PTLD, and 17 patients remain alive. Age, sex, organ source, LDH, stage, presence of extranodal disease, or presentation with B symptoms did not influence overall survival when examined by Cox proportional hazard model. Thirteen patients retained their graft function throughout PTLD treatment. This study confirms the ability to treat a significant proportion of PTLD patients with chemotherapy or surgical resection (depending on presentation), without sacrificing graft function in those receiving chemotherapy.

KW - Lymphoproliferative disorder

KW - Post-transplant

UR - http://www.scopus.com/inward/record.url?scp=33847685301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847685301&partnerID=8YFLogxK

U2 - 10.1002/ajh.20795

DO - 10.1002/ajh.20795

M3 - Article

C2 - 17022049

AN - SCOPUS:33847685301

VL - 82

SP - 208

EP - 214

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -